{'fraction_non_alphanumeric': 0.03571428571428571, 'fraction_numerical': 0.03477443609022556, 'mean_word_length': 5.614906832298137, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression of gp 185HER‐2 in human cutaneous melanoma: Implications for experimental immunotherapeutics

Over‐expression of the HER‐2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp 185 HER‐2 in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER‐2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti‐gp 185HER‐2 MAb, in conditions in which the growth of SKBr‐3 breast‐carcinoma cells was severely impaired. However, immunotoxins to gp 185HER‐2 were able to kill gp 185Her‐2‐positive melanoma cells. These data indicate that low levels of gp 185HER‐2 are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp 185HBR‐2 appears a suitable target for immunotherapy of cutaneous melanoma.